Dermira Announces Proposed Public Offering of Common Stock
28 févr. 2017 17h13 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
28 févr. 2017 16h05 HE
|
Dermira, Inc.
-- Planned submission of NDA for glycopyrronium tosylate (formerly DRM04) in 2H17 on schedule after pre-NDA meeting with FDA ---- Management to host webcast and conference call today 4:30 p.m. ET /...
Dermira Data from DRM04 and Olumacostat Glasaretil Clinical Programs to Be Presented at American Academy of Dermatology Annual Meeting
27 févr. 2017 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
08 févr. 2017 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
19 janv. 2017 02h00 HE
|
Dermira, Inc.
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trialsSubmission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and...
Dermira Provides Corporate Update
06 janv. 2017 07h30 HE
|
Dermira, Inc.
Treatment period for DRM04 ARIDO trial completedPhase 3 acne clinical program for olumacostat glasaretil initiatedTopline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected...
Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
05 janv. 2017 07h30 HE
|
Dermira, Inc.
Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership TeamWorked on several leading dermatology brands including ACZONE® and BOTOX® during...
Dermira Elects Emmanuel Caeymaex to Board of Directors
04 janv. 2017 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Initiates Phase 3 Clinical Program in Acne
03 janv. 2017 07h30 HE
|
Dermira, Inc.
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgarisTwo Phase 3 trials expected to enroll a total of 1,400...
Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
08 déc. 2016 02h00 HE
|
Dermira, Inc.
Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development programFindings confirm CIMZIA results observed in earlier CIMPASI-2 trialResults from third and...